ACOR Acorda Therapeutics, Inc.

15.10
-0.20  -1%
Previous Close 15.30
Open 15.30
Price To book 1.06
Market Cap 706.05M
Shares 46,758,000
Volume 455,676
Short Ratio 5.25
Av. Daily Volume 1,132,130

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17859978
  2. 8-K - Current report 17853472
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827506
  4. 8-K - Current report 17786131
  5. DEF 14A - Other definitive proxy statements 17776556

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 2 to be initiated by the end of 2017.
CVT-427
Migraine
Phase 3 data due 1Q 2018.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing due by the end of 2Q 2017.
CVT-301
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Acorda to Present New INBRIJA™ (Levodopa Inhalation Powder) Phase 3 Data at Upcoming MDS Congress
  2. Acorda to Present at the Deutsche Bank 42nd Annual Healthcare Conference
  3. Edited Transcript of ACOR earnings conference call or presentation 27-Apr-17 12:30pm GMT
  4. Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss
  5. Acorda Expands Alexa Skill Offering for Parkinson’s Awareness Month
  6. Acorda Shares Fall 5% in an Earnings Miss
  7. Acorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses
  8. Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports
  9. Acorda Puts 4 Drugs On Back Burner After Patent Setback
  10. CORRECTING and REPLACING Acorda Provides Financial and Pipeline Update for First Quarter 2017
  11. Acorda reports 1Q loss
  12. Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017
  13. Bass Battled U.S. Drug Patents and Prices But Lost to ‘Cabal’
  14. ACORDA NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics Inc. To Contact The Firm
  15. Acorda Trims 20% Of Workforce, But Looming Cuts Could Be Deeper
  16. Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline
  17. Acorda CEO Risks All, Loses Nothing, When Drug Patent Strategy Backfires, Employees Fired
  18. Acorda Therapeutics to cut 20 pct of workforce
  19. Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs
  20. Why Acorda Therapeutics Inc Plummeted for a Second Straight Day

SEC Filings

  1. CT ORDER - Confidential treatment order 17859978
  2. 8-K - Current report 17853472
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827506
  4. 8-K - Current report 17786131
  5. DEF 14A - Other definitive proxy statements 17776556
  6. 8-K - Current report 17746665
  7. 8-K - Current report 17729400
  8. 8-K - Current report 17720630
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17682185
  10. 8-K - Current report 17678894